Please assess the completion status of the following clinical trial:

Trial Title: A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants ≥ 18 years of age.~* Histologically or cytologically documented breast cancer.~* Metastatic or unresectable locally advanced/recurrent breast cancer.~* HER2-positive disease by prospective laboratory confirmation.~* Disease progression on the last regimen received as defined by the investigator.~* Prior treatment with an trastuzumab, a taxane, and lapatinib.~* Disease progression after at least two regimens of HER2-directed therapy in the metastatic or unresectable locally advanced/recurrent setting.~* Adequate organ function, as evidenced by laboratory results.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.~* Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or multi gated acquisition scan.~Exclusion Criteria:~* Chemotherapy ≤ 21 days before first study treatment.~* Trastuzumab ≤ 21 days before first study treatment.~* Lapatinib ≤ 14 days before first study treatment.~* Prior enrollment in a trastuzumab emtansine containing study, regardless whether the patient received prior trastuzumab emtansine.~* Brain metastases that are untreated or symptomatic, or require any radiation, surgery or corticosteroid therapy to control symptoms within 1 month of randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab emtansine (Type: EXPERIMENTAL): Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
- Treatment of physician's choice (Type: ACTIVE_COMPARATOR): Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).